had two recurrent episodes of multiple evanescent white dot syndrome (MEWDS) two weeks after the second dose of the Moderna COVID-19 vaccine and again after the second booster dose; This literature-non-study case was reported in a literature article and describes the occurrence of RETINAL WHITE DOTS SYNDROME (had two recurrent episodes of multiple evanescent white dot syndrome (MEWDS) two weeks after the second dose of the Moderna COVID-19 vaccine and again after the second booster dose) in a 31-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.       No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced RETINAL WHITE DOTS SYNDROME (had two recurrent episodes of multiple evanescent white dot syndrome (MEWDS) two weeks after the second dose of the Moderna COVID-19 vaccine and again after the second booster dose) (seriousness criterion medically significant). At the time of the report, RETINAL WHITE DOTS SYNDROME (had two recurrent episodes of multiple evanescent white dot syndrome (MEWDS) two weeks after the last dose of the Moderna COVID-19 vaccine and again after the last booster dose) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Ophthalmological examination: Dilated fundus findings were remarkable for unilateral, small whitish-yellow dots scattered around posterior pole of the left eye, consistent with a diagnosis of MEWDS after taking the second dose and recurrence of symptoms with an enlarged scotoma and similar examination findings after taking the second booster dose.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.   The patient was evaluated for a temporal scotoma and photopsias that started two weeks after the second dose of the Moderna COVID-19 vaccine. The symptoms resolved three months later without treatment. Approximately one year after the first vaccine, the patient received the second Moderna COVID-19 vaccine booster and experienced a recurrence of symptoms. The patient was treated with a course of unspecified systemic corticosteroids with subsequent clinical improvement.  The authors concluded that, although uveitis following COVID-19 vaccines was rare, this case highlighted a need for increased awareness amongst practitioners regarding COVID-19-vaccine-associated onset or recurrence of ocular inflammatory diseases. Company comment-This literature-non-study case, concerns a female patient aged 31 years with no medical history reported, who experienced the unexpected serious (medically significant) event of Retinal white dots syndrome about two weeks after second dose of mRNA-1273 vaccine in the covid 19 vaccination series. Patient was evaluated for a temporal scotoma and photopsias that started two weeks after the second dose of the Moderna COVID-19 vaccine. Dilated fundus findings were remarkable for unilateral, small whitish-yellow dots scattered around posterior pole of the left eye, consistent with a diagnosis of MEWDS. The symptoms resolved three months later without treatment. Approximately a year after the first vaccine, the patient received the second booster and had recurrence of symptoms with an enlarged scotoma and similar examination findings. She was treated with a course of systemic corticosteroids with subsequent clinical improvement. No further information on risk factors, co morbidities, detailed clinical course, management of the event was available in the report. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This literature-non-study case, concerns a female patient aged 31 years with no medical history reported, who experienced the unexpected serious (medically significant) event of Retinal white dots syndrome about two weeks after second dose of mRNA-1273 vaccine in the covid 19 vaccination series. Patient was evaluated for a temporal scotoma and photopsias that started two weeks after the second dose of the Moderna COVID-19 vaccine. Dilated fundus findings were remarkable for unilateral, small whitish-yellow dots scattered around posterior pole of the left eye, consistent with a diagnosis of MEWDS. The symptoms resolved three months later without treatment. Approximately a year after the first vaccine, the patient received the second booster and had recurrence of symptoms with an enlarged scotoma and similar examination findings. She was treated with a course of systemic corticosteroids with subsequent clinical improvement. No further information on risk factors, co morbidities, detailed clinical course, management of the event was available in the report. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.